Display options
Cite
Ogawa D, Ansari K, Nowicki MO, et al. MicroRNA-451 Inhibits Migration of Glioblastoma while Making It More Susceptible to Conventional Therapy. Noncoding RNA. 2019;5(1)doi: 10.3390/ncrna5010025.
Ogawa, D., Ansari, K., Nowicki, M. O., Salińska, E., Bronisz, A., & Godlewski, J. (2019). MicroRNA-451 Inhibits Migration of Glioblastoma while Making It More Susceptible to Conventional Therapy. Non-coding RNA, 5(1), . https://doi.org/10.3390/ncrna5010025
Ogawa, Daisuke, et al. "MicroRNA-451 Inhibits Migration of Glioblastoma while Making It More Susceptible to Conventional Therapy." Non-coding RNA vol. 5,1 (2019). doi: https://doi.org/10.3390/ncrna5010025
Ogawa D, Ansari K, Nowicki MO, Salińska E, Bronisz A, Godlewski J. MicroRNA-451 Inhibits Migration of Glioblastoma while Making It More Susceptible to Conventional Therapy. Noncoding RNA. 2019 Mar 15;5(1). doi: 10.3390/ncrna5010025. PMID: 30875963; PMCID: PMC6468936.
Copy Download .nbib Format: NLM
Share it on

Noncoding RNA. 2019 Mar 15;5(1). doi: 10.3390/ncrna5010025.

MicroRNA-451 Inhibits Migration of Glioblastoma while Making It More Susceptible to Conventional Therapy.

Non-coding RNA

Daisuke Ogawa, Khairul Ansari, Michal O Nowicki, Elżbieta Salińska, Agnieszka Bronisz, Jakub Godlewski

Affiliations

  1. Department of Neurosurgery, Harvey Cushing Neuro-oncology Laboratories, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. [email protected].
  2. Department of Neurological Surgery, Kagawa University Hospital, Miki-cho, 761-0793 Kagawa, Japan. [email protected].
  3. Department of Neurosurgery, Harvey Cushing Neuro-oncology Laboratories, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. [email protected].
  4. Division of Neurosurgery, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA. [email protected].
  5. Department of Neurosurgery, Harvey Cushing Neuro-oncology Laboratories, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. [email protected].
  6. Department of Neurochemistry, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland. [email protected].
  7. Department of Neurosurgery, Harvey Cushing Neuro-oncology Laboratories, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. [email protected].
  8. Department of Neurosurgery, Harvey Cushing Neuro-oncology Laboratories, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. [email protected].

PMID: 30875963 PMCID: PMC6468936 DOI: 10.3390/ncrna5010025

Abstract

Malignant glioblastoma (GBM, glioma) is the most common and aggressive primary adult brain tumor. The prognosis of GBM patients remains poor, despite surgery, radiation and chemotherapy. The major obstacles for successful remedy are invasiveness and therapy resistance of GBM cells. Invasive glioma cells leave primary tumor core and infiltrate surrounding normal brain leading to inevitable recurrence, even after surgical resection, radiation and chemotherapy. Therapy resistance allowing for selection of more aggressive and resistant sub-populations including GBM stem-like cells (GSCs) upon treatment is another serious impediment to successful treatment. Through their regulation of multiple genes, microRNAs can orchestrate complex programs of gene expression and act as master regulators of cellular processes. MicroRNA-based therapeutics could thus impact broad cellular programs, leading to inhibition of invasion and sensitization to radio/chemotherapy. Our data show that miR-451 attenuates glioma cell migration in vitro and invasion in vivo. In addition, we have found that miR-451 sensitizes glioma cells to conventional chemo- and radio-therapy. Our data also show that miR-451 is regulated in vivo by AMPK pathway and that AMPK/miR-451 loop has the ability to switch between proliferative and migratory pattern of glioma cells behavior. We therefore postulate that AMPK/miR-451 negative reciprocal feedback loop allows GBM cells/GSCs to adapt to tumor "ecosystem" by metabolic and behavioral flexibility, and that disruption of such a loop reduces invasiveness and diminishes therapy resistance.

Keywords: AMPK; glioblastoma; invasiveness; microRNA; therapy resistance

References

  1. Int J Cancer. 1999 Mar 31;81(1):104-12 - PubMed
  2. Cancer Res. 2001 Mar 15;61(6):2744-50 - PubMed
  3. Biochem Soc Trans. 2002 Nov;30(Pt 6):1064-70 - PubMed
  4. Science. 1956 Feb 24;123(3191):309-14 - PubMed
  5. J Biol. 2003;2(4):28 - PubMed
  6. EMBO J. 2004 Feb 25;23(4):833-43 - PubMed
  7. Mol Cell Biol. 2004 Apr;24(8):3526-35 - PubMed
  8. Neurosci Biobehav Rev. 2004 Apr;28(2):143-80 - PubMed
  9. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  10. J Pathol. 2005 Dec;207(4):396-401 - PubMed
  11. Eur J Pharmacol. 2006 Aug 7;542(1-3):8-15 - PubMed
  12. Mol Cell Biol. 2006 Jul;26(14):5336-47 - PubMed
  13. Diabetologia. 2008 Feb;51(2):216-26 - PubMed
  14. Cancer Res. 2008 May 15;68(10):3566-72 - PubMed
  15. Mol Cancer Ther. 2008 Jul;7(7):2152-9 - PubMed
  16. Neuro Oncol. 2008 Oct;10(5):690-9 - PubMed
  17. Biochem Biophys Res Commun. 2008 Nov 7;376(1):86-90 - PubMed
  18. Cancer Res. 2008 Sep 15;68(18):7270-7 - PubMed
  19. Cancer Res. 2008 Nov 15;68(22):9125-30 - PubMed
  20. Nat Cell Biol. 2009 Mar;11(3):320-7 - PubMed
  21. J Neurosci. 2009 Mar 4;29(9):2997-3008 - PubMed
  22. Lancet Oncol. 2009 May;10(5):459-66 - PubMed
  23. Mol Cancer Ther. 2009 Apr;8(4):733-41 - PubMed
  24. Cell Death Differ. 2010 Feb;17(2):221-8 - PubMed
  25. Physiol Rev. 2009 Jul;89(3):1025-78 - PubMed
  26. Trends Biochem Sci. 2009 Oct;34(10):491-9 - PubMed
  27. J Gen Physiol. 1927 Mar 7;8(6):519-30 - PubMed
  28. J Neurosci. 2009 Dec 2;29(48):15161-8 - PubMed
  29. Mol Cell. 2010 Mar 12;37(5):620-32 - PubMed
  30. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):221-9 - PubMed
  31. Int J Cancer. 2011 May 1;128(9):2230-9 - PubMed
  32. Cell Cycle. 2010 Jul 15;9(14):2742-8 - PubMed
  33. Genes Dev. 2010 Aug 1;24(15):1614-9 - PubMed
  34. Genes Dev. 2010 Aug 1;24(15):1620-33 - PubMed
  35. J Exp Clin Cancer Res. 2011 Feb 17;30:20 - PubMed
  36. Handb Exp Pharmacol. 2011;(203):303-30 - PubMed
  37. Genes Dev. 2011 May 15;25(10):1041-51 - PubMed
  38. J Cell Mol Med. 2012 Mar;16(3):616-26 - PubMed
  39. Mol Oncol. 2011 Aug;5(4):374-86 - PubMed
  40. Oncogene. 2012 Jan 5;31(1):39-47 - PubMed
  41. Neurosurgery. 2011 Jun;68(6):N21-2 - PubMed
  42. PLoS One. 2011;6(8):e23872 - PubMed
  43. Cancer Res. 2011 Sep 15;71(18):5945-9 - PubMed
  44. Stem Cells. 2011 Nov;29(11):1661-71 - PubMed
  45. Mol Cancer. 2011 Oct 11;10:128 - PubMed
  46. Cell Cycle. 2011 Nov 1;10(21):3658-77 - PubMed
  47. Nat Cell Biol. 2011 Dec 18;14(2):159-67 - PubMed
  48. PLoS One. 2011;6(12):e28293 - PubMed
  49. Radiother Oncol. 2012 Mar;102(3):459-65 - PubMed
  50. Neurochem Res. 2012 Jun;37(6):1192-200 - PubMed
  51. Nature. 2012 Mar 28;483(7391):608-12 - PubMed
  52. Cell Metab. 2012 Apr 4;15(4):492-504 - PubMed
  53. Carcinogenesis. 2012 Jun;33(6):1126-33 - PubMed
  54. Expert Rev Anticancer Ther. 2012 May;12(5):635-42 - PubMed
  55. Stem Cells. 2012 Oct;30(10):2221-33 - PubMed
  56. BMC Cancer. 2012 Aug 16;12:357 - PubMed
  57. Gene Ther. 2013 Jul;20(7):742-50 - PubMed
  58. J Neurooncol. 2013 Apr;112(2):153-63 - PubMed
  59. Conf Proc IEEE Eng Med Biol Soc. 2012;2012:6620-3 - PubMed
  60. Cancer Res. 2013 Apr 15;73(8):2628-38 - PubMed
  61. Front Oncol. 2013 Mar 18;3:53 - PubMed
  62. Cell Logist. 2012 Oct 1;2(4):197-202 - PubMed
  63. Cell. 2013 May 23;153(5):1064-79 - PubMed
  64. Neuro Oncol. 2013 Sep;15(9):1212-24 - PubMed
  65. Drug Resist Updat. 2013 Jul-Nov;16(3-5):47-59 - PubMed
  66. Cancer Cell. 2013 Jun 10;23(6):713-5 - PubMed
  67. Front Oncol. 2013 Jun 13;3:153 - PubMed
  68. Nat Neurosci. 2013 Oct;16(10):1373-82 - PubMed
  69. Cancer Biol Ther. 2014 Feb;15(2):156-69 - PubMed
  70. Cell. 2013 Oct 10;155(2):462-77 - PubMed
  71. Mol Cancer. 2013 Oct 20;12(1):123 - PubMed
  72. Cancer Res. 2014 Feb 1;74(3):738-750 - PubMed
  73. Mol Cancer Ther. 2014 Mar;13(3):596-605 - PubMed
  74. Science. 2014 Jun 20;344(6190):1396-401 - PubMed
  75. J Biol Chem. 2014 Aug 15;289(33):22850-64 - PubMed
  76. PLoS One. 2014 Jul 10;9(7):e101239 - PubMed
  77. Oncotarget. 2014 Aug 15;5(15):6113-29 - PubMed
  78. J Neurosci. 2014 Jul 30;34(31):10192-205 - PubMed
  79. Breast Cancer Res. 2014 Aug 06;16(4):420 - PubMed
  80. J Cell Mol Med. 2014 Nov;18(11):2266-74 - PubMed
  81. PLoS One. 2014 Sep 19;9(9):e107502 - PubMed
  82. Am J Pathol. 2014 Oct;184(10):2828-39 - PubMed
  83. Curr Opin Cell Biol. 2015 Apr;33:1-7 - PubMed
  84. Neuro Oncol. 2015 May;17(5):652-62 - PubMed
  85. Cell Metab. 2014 Dec 2;20(6):939-52 - PubMed
  86. Eur J Cancer. 2014 Dec;50(18):3187-97 - PubMed
  87. Int J Clin Exp Pathol. 2014 Oct 15;7(11):7653-62 - PubMed
  88. Nat Rev Clin Oncol. 2015 Feb;12(2):69-70 - PubMed
  89. Arch Pharm Res. 2015 Mar;38(3):346-57 - PubMed
  90. PLoS One. 2015 Jan 28;10(1):e0114370 - PubMed
  91. Nat Commun. 2015 Feb 05;6:6053 - PubMed
  92. Oncotarget. 2015 Feb 28;6(6):3770-83 - PubMed
  93. J R Soc Interface. 2015 May 6;12(106):null - PubMed
  94. Nat Rev Cancer. 2015 May;15(5):302-10 - PubMed
  95. Cell Rep. 2015 May 12;11(6):902-909 - PubMed
  96. Oncotarget. 2015 Jul 30;6(21):18613-30 - PubMed
  97. Oncotarget. 2015 Jul 20;6(20):17851-2 - PubMed
  98. Semin Cell Dev Biol. 2015 Jul;43:3-10 - PubMed
  99. Cancer Res. 2016 May 15;76(10):2876-81 - PubMed
  100. Cell Rep. 2016 Jun 14;15(11):2500-9 - PubMed
  101. Oncol Rep. 2016 Oct;36(4):2049-58 - PubMed
  102. Mol Cell Biochem. 2016 Dec;423(1-2):85-91 - PubMed
  103. Stem Cell Reports. 2017 Jun 6;8(6):1497-1505 - PubMed
  104. Cell Rep. 2017 Jun 6;19(10):2026-2032 - PubMed
  105. Vitam Horm. 2017;105:249-271 - PubMed
  106. Cell Death Dis. 2017 Oct 5;8(10):e3071 - PubMed
  107. J Cell Biochem. 2018 Jan 6;:null - PubMed
  108. Onco Targets Ther. 2018 Jul 24;11:4301-4314 - PubMed
  109. Eur Rev Med Pharmacol Sci. 2018 Sep;22(17):5554-5561 - PubMed

Publication Types

Grant support